Showing results (161-170 of 186) with videos related to
Sort By:
Pageof 19
JAMA|October 13, 2005
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failureCatherine Demers, John J V McMurray, Karl Swedberg, et al.European Heart Journal|September 30, 2008
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeStuart J Pocock, John J V McMurray, Joanna Dobson, et al.Journal of the American College of Cardiology|December 6, 2008
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) ProgramPeter A Meredith, Jan Ostergren, Inder Anand, et al.Journal of the American College of Cardiology|July 3, 2007
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke DatabankG Michael Felker, Larry A Allen, Stuart J Pocock, et al.American Heart Journal|March 30, 2013
Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research ConsortiumPhilip Sager, Jeffrey Heilbraun, J Rick Turner, et al.European Heart Journal|April 17, 2008
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeMichael R MacDonald, Mark C Petrie, Fumi Varyani, et al.American Heart Journal|April 29, 2006
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programAnique Ducharme, Karl Swedberg, Marc A Pfeffer, et al.Journal of the American College of Cardiology|May 7, 2011
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudyBenjamin M Scirica, Christopher P Cannon, Håkan Emanuelsson, et al.Journal of the American College of Cardiology|November 13, 2007
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM ProgramAkshay S Desai, Karl Swedberg, John J V McMurray, et al.Circulation|June 15, 2007
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.Pageof 19